Section Arrow
TARA.NASDAQ
- Protara Therapeutics
Quotes are at least 15-min delayed:2024/12/24 12:28 EST
Last
 5.15
0 (0.00%)
Day High 
5.2 
Prev. Close
5.15 
1-M High
10.48 
Volume 
224.86K 
Bid
5.14
Ask
5.15
Day Low
5.05 
Open
5.15 
1-M Low
2.3562 
Market Cap 
176.75M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.68 
20-SMA 4.79 
50-SMA 3.29 
52-W High 10.48 
52-W Low 1.595 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.64/-2.23
Enterprise Value
181.23M
Balance Sheet
Book Value Per Share
2.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3899-0.0132-3.27%-- 
CMNDClearmind Medicine1.65+0.43+35.25%0.16PE
CEROCERo Therapeutics Holdings0.0599+0.0094+18.61%-- 
RXRXRecursion Pharmaceuticals7.2+0.21+3.00%-- 
CDTConduit Pharmaceuticals0.0596+0.0051+9.36%-- 
Quotes are at least 15-min delayed:2024/12/24 12:28 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatmentoptions. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.